This position paper is intended to help to structure and to standardize therapy monitoring in patients with metastatic castration-resistant prostate cancer (mCRPC). With the treatment options available today, patients with metastatic disease can often maintain good quality of life and stable disease for several years. It is crucial that once a therapy becomes insufficiently effective that it be replaced in a timely manner by a new treatment option. From a prognostic point of view, it is important that patients receive as many as possible and in the ideal case all currently available treatment options.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00120-014-3491-7 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Heterogeneity of the Treatment Effect with PARP Inhibitors in Metastatic Castration-resistant Prostate Cancer: A Living Interactive Systematic Review and Meta-analysis.
Eur Urol
January 2025
Department of Oncology, City of Hope Cancer Center, Goodyear, AZ, USA.
Background And Objective: Selection of patients harboring mutations in homologous recombination repair (HRR) genes for treatment with a PARP inhibitor (PARPi) is challenging in metastatic castration-resistant prostate cancer (mCRPC). To gain further insight, we quantitatively assessed the differential efficacy of PARPi therapy among patients with mCRPC and different HRR gene mutations.
Methods: This living meta-analysis (LMA) was conducted using the Living Interactive Evidence synthesis framework.
Association between DNA damage repair alterations and outcomes to Lu-PSMA-617 in advanced prostate cancer.
ESMO Open
January 2025
Dana-Farber Cancer Institute, Boston, USA. Electronic address:
Background: Lu-prostate-specific membrane antigen (PSMA)-617 (LuPSMA) is a radionuclide therapy approved for patients with PSMA-avid metastatic castrate-resistant prostate cancer (mCRPC). We evaluated whether alterations in the DNA damage repair (DDR) pathway were associated with outcomes to LuPSMA.
Patients And Methods: We identified an institutional cohort of men (n = 134) treated with ≥2 cycles of LuPSMA who had panel-based germline and/or tumor genomic sequencing.
Exhalation of Rn-219 by patients treated with Radium-223.
EJNMMI Phys
January 2025
Department for Radiation Protection and Medical Physics, Hannover Medical School, Carl-Neuberg- Str. 1, 30625, Hannover, Germany.
Background: Treatment with Ra-223 dichloride is approved for the therapy of castration resistant prostate cancer (CRPC) with symptomatic bone metastases and no known visceral metastases in Europe since 2013, and Ra-223 is under discussion for labelling other molecules and nanoparticles. The direct progeny of Ra-223 is Rn-219, also known as actinon, a radioactive noble gas with a half-life of 3.98 s.
View Article and Find Full Text PDFCorrection: Radiopharmacokinetic modelling and radiation dose assessment of Ra used for treatment of metastatic castration-resistant prostate cancer.
EJNMMI Phys
January 2025
Institute of Radiation Medicine, Helmholtz Zentrum München, German Research Center for Environmental Health, Ingolstädter Landstraße 1, 85764, Neuherberg, Germany.
Prognostic F-flotufolastat PET parameters for outcome assessment of Lu-labeled PSMA-targeted radioligand therapy in metastatic castration-resistant prostate cancer.
Eur J Nucl Med Mol Imaging
January 2025
Department of Nuclear Medicine, School of Medicine, Technical University of Munich, Munich, Germany.
Purpose: This retrospective analysis evaluates baseline F-flotufolastat positron emission tomography (PET) parameters as prognostic parameters for treatment response and outcome in patients with metastatic castration-resistant prostate cancer (mCRPC) undergoing treatment with [Lu]Lu-PSMA-I&T.
Methods: A total of 188 mCRPC patients with baseline F-flotufolastat PET scans were included. Tumor lesions were semiautomatically delineated, with imaging parameters including volume-based and standardized uptake value (SUV)-based metrics.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!